FDA Approves First Oral Pill To Treat Anemia In People With Chronic Kidney Disease

On February 1, 2023, the U.S. Food and Drug Administration (FDA) approved the first oral pill to treat anemia in those with chronic kidney disease (CKD). Jesduvroq (daprodustat), by biopharmaceutical company GSK, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for adults who have been receiving dialysis for at least four months. Jesduvroq is a tablet available in 5 dosage strengths: 1 milligram (mg), 2 mg, 4 mg, 6 mg, and 8 mg. Information is not available regarding when Jesduvroq may be commercially available.
For individuals with CKD who require dialysis, the kidneys are unable to . . .